An effective medical partnership in Nagasaki, Japan for patients with rheumatoid arthritis.

about

An effective medical partnership in Nagasaki, Japan for patients with rheumatoid arthritis.

Item

http://www.wikidata.org/entity/Q39967995

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

An effective medical partnersh ...... nts with rheumatoid arthritis.

@en

An effective medical partnersh ...... nts with rheumatoid arthritis.

@nl

type

Item

label

An effective medical partnersh ...... nts with rheumatoid arthritis.

@en

An effective medical partnersh ...... nts with rheumatoid arthritis.

@nl

prefLabel

An effective medical partnersh ...... nts with rheumatoid arthritis.

@en

An effective medical partnersh ...... nts with rheumatoid arthritis.

@nl

P1476

An effective medical partnersh ...... nts with rheumatoid arthritis.

@en

P2093

Atsushi Kawakami

http://www.w3.org/2001/XMLSchema#string

Hideki Nakamura

http://www.w3.org/2001/XMLSchema#string

Naoki Iwamoto

http://www.w3.org/2001/XMLSchema#string

Takehiro Matsumoto

http://www.w3.org/2001/XMLSchema#string

P2860

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study.

Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study.

Phase III, multicenter, open-label, long-term study of the safety of abatacept in Japanese patients with rheumatoid arthritis and an inadequate response to conventional or biologic disease-modifying antirheumatic drugs.

Treating rheumatoid arthritis to target: recommendations of an international task force.

Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry

Diagnostic performance of measuring antibodies to the glycopeptidolipid core antigen specific to Mycobacterium avium complex in patients with rheumatoid arthritis: results from a cross-sectional observational study

Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study.

Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research.

Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.

P304

878-884

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/14397595.2016.1158904

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-02-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26916043

http://www.w3.org/2001/XMLSchema#string